Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults

Expert Review of Clinical Pharmacology
William V Bobo

Abstract

This article reviews the pharmacological profile and published efficacy and tolerability/safety data of iloperidone, asenapine and lurasidone, the most recent atypical antipsychotics to be approved in the USA for the treatment of schizophrenia. All three agents are similar in terms of overall efficacy and low propensity for clinically significant weight gain or adverse changes in glycemic or lipid profile. However, these agents differ from one another in terms of formulations, pharmacokinetics, and dosing and nonmetabolic adverse effect profile. For each drug, comparative and real-world effectiveness studies are lacking, as are effectiveness and safety data in elderly, young and pregnant/nursing patients. As such, the exact place of iloperidone, asenapine and lurasidone within the broader antipsychotic armamentarium is currently difficult to establish.

References

Feb 6, 2014·Expert Opinion on Drug Metabolism & Toxicology·Edoardo Spina, Jose de Leon
May 25, 2016·The Psychiatric Clinics of North America·Donna AmesLynn M Yudofsky
Nov 21, 2015·AAPS PharmSciTech·Sunny ShahJayant Chavda
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura
May 7, 2020·Frontiers in Endocrinology·Samantha Alvarez-HerreraLenin Pavón

Citations

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jul 1, 1990·Schizophrenia Research·D AddingtonB Schissel
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jun 1, 1985·The Journal of Nervous and Mental Disease·R D LaneS I Kramer
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Dec 19, 1996·European Journal of Pharmacology·S KongsamutA Sandrasagra
Jan 1, 1997·Schizophrenia Bulletin·W S FentonR K Heinssen
Jan 1, 1997·Schizophrenia Bulletin·R R Conley, Robert W Buchanan
Oct 21, 2000·The British Journal of Psychiatry : the Journal of Mental Science·S BrownB Barraclough
Nov 3, 2001·The American Journal of Psychiatry·A H Glassman, J T Bigger
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hans O KalkmanD Hoyer
Jan 5, 2002·CNS Drugs·Daniel TarsyFrank I Tarazi
May 10, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Natarajan Subramanian, Hans O Kalkman
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Apr 10, 2003·The Psychiatric Clinics of North America·Tonmoy Sharma, Lena Antonova
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Jul 29, 2004·Schizophrenia Bulletin·Anthony F LehmanDonald M Steinwachs
Mar 24, 2005·The International Journal of Neuropsychopharmacology·Neil D WoodwardDavid H Zald
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Jul 15, 2005·The Journal of Clinical Psychiatry·Trisha SuppesTexas Consensus Conference Panel on Medication Treatment of Bipolar Disorder
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 13, 2005·American Heart Journal·Charles H HennekensDaniel E Casey
Nov 14, 2006·Schizophrenia Bulletin·Robert W Buchanan
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeNeurocognitive Working Group
Jul 6, 2007·Expert Review of Neurotherapeutics·James W Michelsen, Jonathan M Meyer
Oct 27, 2007·The Journal of Clinical Psychiatry·Steven G PotkinJohn Panagides
Nov 21, 2007·The British Journal of Psychiatry. Supplement·Stefan Priebe
Feb 1, 2008·Schizophrenia Bulletin·Stefan LeuchtJohn M Kane
Mar 1, 2008·Journal of Psychopharmacology·M ShahidE H F Wong
May 6, 2008·Journal of Clinical Psychopharmacology·Peter J WeidenCurt D Wolfgang
May 6, 2008·Journal of Clinical Psychopharmacology·John M KaneCurt D Wolfgang
May 6, 2008·Journal of Clinical Psychopharmacology·Steven G PotkinCurt D Wolfgang

Related Concepts

Antipsychotic Effect
Schizophrenia
Saphris
Lurasidone
Adverse Effects
Piperidines
Heterocyclic Compounds with 4 or More Rings
Isoindoles
Antipsychotic Agents
Latuda

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Expert Opinion on Drug Safety
Navin V Dargani, Anil K Malhotra
The Annals of Pharmacotherapy
Jehan Marino, Joshua Caballero
Journal of Psychosocial Nursing and Mental Health Services
Robert H Howland
© 2020 Meta ULC. All rights reserved